In a groundbreaking new clinical study in neurology and personalized medicine, an experimental gene-targeting treatment designed specifically for a single patient with a rare genetic form of amyotrophic lateral sclerosis (ALS)…
Translated from the Turkish original by DoktorClub. The Turkish version is the reference text; this English translation has not been separately reviewed by a physician. Read the Turkish original.
In a groundbreaking new clinical study in neurology and personalized medicine, an experimental gene-targeting treatment designed specifically for a single patient with a rare genetic form of amyotrophic lateral sclerosis (ALS) has been reported to produce highly promising initial results. According to the research conducted by Mayo Clinic and published in the journal Med, the treatment, developed using the "N-of-1" (single-patient-focused) concept employed in anticancer and neurodegenerative studies, aims to halt damage in the brain and spinal cord by directly targeting the genetic mutation that causes the disease.
In the study, an antisense oligonucleotide (ASO) treatment, selected from more than 320 candidate molecules in collaboration with the n-Lorem Foundation, was administered via the spinal fluid to the patient, who carries a mutation in the CHCHD10 gene. Data obtained during one year of follow-up and a six-dose treatment course showed a marked 50% decrease in levels of neurofilament light (NfL) protein, the main indicator of nerve cell damage. Over the same period, the patient's breathing, cognitive functions and physical mobility were found to remain stable.
Neurology and genetics experts emphasize that, in rapidly progressive and fatal neurodegenerative diseases such as ALS, stabilization of the clinical condition and such a rapid drop in biomarkers are a major success. ASO technology is said to bind to the faulty RNA that causes the disease, suppressing harmful protein production at the cellular level and thereby protecting motor neurons. This approach demonstrates the power of precision medicine applications that target not just a single gene but each patient's own genetic background.
Experts state that this single-patient study is not yet a standard clinical treatment method, but that it offers a scientific and regulatory framework for the precision medicine and gene therapy infrastructure of the future. This model, developed within Mayo Clinic's "N-of-1" Therapy Program, is expected to accelerate personalized treatment processes in many areas, from rare ultra-precise genetic diseases to common neurological disorders affecting broader populations.
